Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos; A. Bar-Or; B.A.C. Cree; R.J. Fox; C. Giovannoni; P. Vermersch; D.L. Arnold; S. Arnould; T. Schertz; C. Wolf; E. Walstrom; F. Dahlke; L. H. Visser

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

L. Kappos
, A. Bar-Or
, B.A.C. Cree
, R.J. Fox
, C. Giovannoni
, P. Vermersch
, D.L. Arnold
, S. Arnould
, T. Schertz
, C. Wolf
, E. Walstrom
, F. Dahlke
, L. H. Visser

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › Academic › peer review

Originele taal-2	Amerikaans engels
Pagina's (van-tot)	1263-1273
Aantal pagina's	11
Tijdschrift	The Lancet (London)
Volume	391
Status	Gepubliceerd - 1 jan 2018

Citeer dit

@article{f518a54cc5814268be8649b5e109383f,

title = "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study",

author = "L. Kappos and A. Bar-Or and B.A.C. Cree and R.J. Fox and C. Giovannoni and P. Vermersch and D.L. Arnold and S. Arnould and T. Schertz and C. Wolf and E. Walstrom and F. Dahlke and Visser, \{L. H.\}",

year = "2018",

month = jan,

day = "1",

language = "Amerikaans engels",

volume = "391",

pages = "1263--1273",

journal = "The Lancet (London)",

issn = "0140-6736",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study

AU - Kappos, L.

AU - Bar-Or, A.

AU - Cree, B.A.C.

AU - Fox, R.J.

AU - Giovannoni, C.

AU - Vermersch, P.

AU - Arnold, D.L.

AU - Arnould, S.

AU - Schertz, T.

AU - Wolf, C.

AU - Walstrom, E.

AU - Dahlke, F.

AU - Visser, L. H.

PY - 2018/1/1

Y1 - 2018/1/1

M3 - Artikel

SN - 0140-6736

VL - 391

SP - 1263

EP - 1273

JO - The Lancet (London)

JF - The Lancet (London)

ER -